|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/70 | (2006.01) |
| Y02P 20/55 | (2015.11) | ||
| A61K 31/7004 | (2006.01) | ||
| A61K 47/549 | (2017.08) | ||
| A61K 31/7004 | (2013.01) | ||
| A61K 31/7052 | (2006.01) | ||
| A61K 31/7052 | (2013.01) | ||
| A61K 31/7088 | (2006.01) | ||
| A61K 31/713 | (2006.01) | ||
| A61K 31/70 | (2013.01) | ||
| A61K 47/56 | (2017.01) | ||
| A61K 31/7088 | (2013.01) | ||
| A61K 47/54 | (2017.01) | ||
| A61K 31/713 | (2013.01) | ||
| C07H 21/02 | (2006.01) | ||
| C07H 21/02 | (2013.01) | ||
| A61P 3/06 | (2006.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61P 3/10 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 25/14 | (2006.01) | ||
| A61P 3/06 | (2018.01) | ||
| A61P 25/16 | (2006.01) | ||
| A61P 37/02 | (2018.01) | ||
| A61P 25/28 | (2006.01) | ||
| A61P 3/10 | (2018.01) | ||
| A61P 35/00 | (2006.01) | ||
| Y02A 50/30 | (2018.01) | ||
| A61P 37/02 | (2006.01) | ||
| A61K 47/554 | (2017.08) | ||
| A61P 43/00 | (2006.01) | ||
| A61K 47/56 | (2017.08) |
| (11) | Number of the document | 3156077 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16001284.5 |
| Date of filing the European patent application | 2008-12-04 | |
| (97) | Date of publication of the European application | 2017-04-19 |
| (45) | Date of publication and mention of the grant of the patent | 2022-03-09 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 992309 P | 2007-12-04 | US | |
| 13597 P | 2007-12-13 | US | |
| 127751 P | 2008-05-14 | US | |
| 91093 P | 2008-08-22 | US | |
| 97261 P | 2008-09-16 | US |
| (72) |
Manoharan, Muthiah , US
Rajeev, Kallanthottathil, G. , US
Narayanannair, Jayaprakash, K. , US
Jayaraman, Muthusamy , US
|
| (73) |
Arbutus Biopharma Corporation ,
100- 8900 Glenlyon Parkway, Burnaby, BC V5J 5J8,
CA
|
| (54) | TARGETING LIPIDS |
| TARGETING LIPIDS |